Literature DB >> 24680551

Factors predicting the outcome following medical treatment of mesial temporal epilepsy with hippocampal sclerosis.

Javier Sànchez1, Mirella Centanaro2, Juanita Solís2, Fabrizio Delgado2, Luis Yépez2.   

Abstract

PURPOSE: There is a lack of information from South America regarding factors that predict the clinical outcomes of patients treated medically for mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS). This study was conducted to determine which of these factors are the most important.
METHODS: This study included 110 South American patients with MTLE-HS treated with antiepileptic drugs. The factors considered included age, gender, age of epilepsy onset, interval between the lesion and the first seizure, central nervous system infection, traumatic brain injury, perinatal asphyxia, febrile convulsion, history of status epilepticus, types of seizures, site of hippocampal sclerosis (HS), extrahippocampal pathology, and electroencephalogram (EEG) abnormalities. The patients were divided into two groups based on the response to treatment: Group I, seizure free for at least two years; and Group II, not seizure free.
RESULTS: On the multivariate analysis, the factors associated with a poor prognosis in terms of seizure frequency and control following treatment included the presence of an early onset of seizure, more than 10 seizures per month before treatment, and EEG abnormalities.
CONCLUSION: The recognition of risk factors, such as early onset of seizures, more than 10 seizures per month before treatment, and EEG abnormalities, could lead to the identification of risk groups among patients with MTLE-HS and refractory epilepsy, possibly designating these individuals as candidates for early epilepsy surgery.
Copyright © 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epilepsy surgery; Hippocampal sclerosis; Mesial temporal sclerosis; Outcome; Prognostic factors

Mesh:

Substances:

Year:  2014        PMID: 24680551     DOI: 10.1016/j.seizure.2014.03.003

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  5 in total

1.  Pharmacoresistance with newer anti-epileptic drugs in mesial temporal lobe epilepsy with hippocampal sclerosis.

Authors:  Michael S Pohlen; Jingxiao Jin; Ronnie S Tobias; Atul Maheshwari
Journal:  Epilepsy Res       Date:  2017-09-19       Impact factor: 3.045

2.  Predicting seizure freedom after epilepsy surgery, a challenge in clinical practice.

Authors:  Camilo Garcia Gracia; Kevin Chagin; Michael W Kattan; Xinge Ji; Madeleine G Kattan; Lizzie Crotty; Imad Najm; Jorge Gonzalez-Martinez; William Bingaman; Lara Jehi
Journal:  Epilepsy Behav       Date:  2019-04-28       Impact factor: 2.937

3.  Hippocampal CA3 transcriptional modules associated with granule cell alterations and cognitive impairment in refractory mesial temporal lobe epilepsy patients.

Authors:  Silvia Yumi Bando; Fernanda Bernardi Bertonha; Luciana Ramalho Pimentel-Silva; João Gabriel Mansano de Oliveira; Marco Antonio Duarte Carneiro; Mariana Hiromi Manoel Oku; Hung-Tzu Wen; Luiz Henrique Martins Castro; Carlos Alberto Moreira-Filho
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

4.  Community structure analysis of transcriptional networks reveals distinct molecular pathways for early- and late-onset temporal lobe epilepsy with childhood febrile seizures.

Authors:  Carlos Alberto Moreira-Filho; Silvia Yumi Bando; Fernanda Bernardi Bertonha; Priscila Iamashita; Filipi Nascimento Silva; Luciano da Fontoura Costa; Alexandre Valotta Silva; Luiz Henrique Martins Castro; Hung-Tzu Wen
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

Review 5.  Multi-omic strategies applied to the study of pharmacoresistance in mesial temporal lobe epilepsy.

Authors:  Estela M Bruxel; Amanda M do Canto; Danielle C F Bruno; Jaqueline C Geraldis; Iscia Lopes-Cendes
Journal:  Epilepsia Open       Date:  2021-10-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.